Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Aurinia Pharmaceuticals Inc.'s quarterly P/E stands at 2.6x, down 98.8% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 71.4% YoY to 29.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.85 | 2.61 | 12.01 | 14.12 | 12.56 | 224.50 | 18.60 | 142.75 | — | — | — | — | — |
| — | -98.8% | -35.4% | -90.1% | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.62 | 7.17 | 5.11 | 4.33 | 4.47 | 5.54 | 3.94 | 3.60 | 3.59 | 7.16 | 5.09 | 8.33 | 11.36 |
| — | +29.5% | +29.9% | +20.4% | +24.7% | -22.6% | -22.6% | -56.8% | -68.4% | +32.5% | +6.5% | -34.1% | -44.0% | |
| P/B Ratio | 3.38 | 3.81 | 4.11 | 3.62 | 3.19 | 3.51 | 2.75 | 2.26 | 2.01 | 3.42 | 2.83 | 3.52 | 4.00 |
| — | +8.3% | +49.3% | +60.3% | +58.9% | +2.8% | -2.9% | -35.9% | -49.9% | +125.4% | +12.4% | +4.8% | +2.3% | |
| P/FCF | 13.85 | 12.13 | 8.47 | 6.87 | 217.63 | 11.03 | 15.75 | 13.09 | — | 22.65 | — | — | — |
| — | +10.0% | -46.3% | -47.5% | — | -51.3% | — | — | — | +52.1% | — | — | — | |
| EV / EBITDA | 17.82 | 29.58 | 10.89 | 12.44 | 10.56 | 103.51 | 16.80 | 65.72 | — | — | — | — | — |
| — | -71.4% | -35.2% | -81.1% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 17.82 | — | 11.79 | 13.34 | 11.10 | 142.52 | 17.46 | 81.79 | — | — | — | — | — |
| — | — | -32.4% | -83.7% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Aurinia Pharmaceuticals Inc.'s operating margin was 43.1% in Q4 2025, up 2.6 pp QoQ and up 45.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 36.8% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 89.0% | 88.4% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% | 87.6% | 96.2% | 98.8% |
| — | -1.9% | -2.9% | +6.4% | +2.0% | +3.1% | +4.0% | -12.3% | -14.4% | -7.5% | -8.4% | +2.0% | -0.0% | |
| Operating Margin | 37.1% | 43.1% | 40.5% | 28.7% | 35.0% | -2.8% | 17.3% | -2.6% | -21.3% | -65.8% | -29.8% | -39.0% | -86.0% |
| — | +1646.2% | +133.6% | +1184.4% | +264.5% | +95.8% | +158.1% | +93.2% | +75.3% | +33.4% | -75.2% | +69.5% | +50.9% | |
| Net Margin | 101.5% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | -21.4% | -59.6% | -24.7% | -27.7% | -76.2% |
| — | +11351.8% | +102.8% | +2334.2% | +274.9% | +104.0% | +185.8% | +104.6% | +71.9% | +34.9% | -53.1% | +78.0% | +56.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 59.9% | 44.5% | 9.0% | 6.3% | 6.4% | 0.4% | 3.8% | 0.2% | -2.9% | -7.0% | -3.4% | -2.9% | -6.6% |
| — | +11821.1% | +136.0% | +3047.8% | +320.1% | +105.3% | +211.2% | +106.8% | +55.7% | -11.1% | -61.6% | +64.0% | +18.9% | |
| ROA | 44.1% | 33.0% | 6.1% | 4.3% | 4.4% | 0.3% | 2.7% | 0.1% | -2.0% | -4.9% | -2.4% | -2.3% | -5.7% |
| — | +12586.5% | +129.0% | +2977.0% | +319.1% | +105.3% | +209.8% | +106.0% | +64.5% | +10.3% | -31.5% | +68.0% | +20.7% | |
| ROIC | 16.6% | 5.3% | 6.1% | 4.2% | 4.5% | -0.3% | 2.1% | -0.3% | -2.0% | -5.1% | -2.9% | -3.4% | -7.1% |
| — | +1808.2% | +194.9% | +1564.5% | +325.2% | +94.0% | +171.8% | +91.6% | +71.9% | +18.9% | -26.0% | +62.3% | +27.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Aurinia Pharmaceuticals Inc.'s Debt/EBITDA ratio is 4.0x, up from 2.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 14.9% YoY to 5.25x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.21 | 0.24 | 0.22 | 0.21 | 0.23 | 0.24 | 0.25 | 0.26 | 0.24 | 0.26 | 0.02 |
| — | -38.8% | -5.6% | +3.5% | -9.7% | -18.6% | -4.8% | -8.6% | +1112.4% | +1194.6% | +1130.0% | +1204.0% | +6.2% | |
| Debt / EBITDA | 0.71 | 4.01 | 2.26 | 3.28 | 2.92 | 24.86 | 5.28 | 25.82 | — | — | — | — | — |
| — | -83.9% | -57.2% | -87.3% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.25 | 5.25 | 5.76 | 5.23 | 5.93 | 4.57 | 5.60 | 5.33 | 5.60 | 5.50 | 5.77 | 6.75 | 10.08 |
| — | +14.9% | +2.7% | -1.9% | +5.8% | -17.0% | -2.9% | -21.0% | -44.4% | -42.7% | -47.6% | -48.5% | -28.6% | |
| Quick Ratio | 4.76 | 4.76 | 5.17 | 4.63 | 5.26 | 4.17 | 5.11 | 4.82 | 5.05 | 4.99 | 5.33 | 6.21 | 9.32 |
| — | +14.3% | +1.1% | -4.0% | +4.2% | -16.5% | -4.1% | -22.3% | -45.9% | -44.9% | -48.8% | -49.7% | -30.1% | |
| Interest Coverage | — | — | — | 17.98 | 20.48 | -1.46 | 9.73 | -1.26 | -8.34 | -22.65 | -11.62 | -248.77 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAurinia Pharmaceuticals Inc.'s current P/E is 6.8x. The average P/E over the last 4 quarters is 10.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aurinia Pharmaceuticals Inc.'s current operating margin is 37.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aurinia Pharmaceuticals Inc.'s business trajectory between earnings reports.